EUVIMEDEUVIMED entdecken
Open Access

Genomic hallmarks of depot medroxyprogesterone acetate-associated meningiomas

Sakibul Huq iD, Taylor A Gatesman iD, Hussam Abou-Al-Shaar iD, David R Raleigh iD, Constantinos G Hadjipanayis iD, James C Bayley iD, Georgios A Zenonos, Thomas M Pearce iD, Daniel F Marker iD, Sameer Agnihotri iD, Paul A Gardner iD

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noag136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Sakibul Huq und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Meningioma, Medroxyprogesterone Acetate, Meningeal Neoplasms, Genomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH/NINDS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Population-based studies have linked progestin exposure to increased meningioma risk. However, the molecular basis of meningiomas associated with depot medroxyprogesterone acetate (DMPA)—a common injectable contraceptive—remains undefined.

Methods

We performed an integrated clinicopathologic and genomic analysis of meningiomas from 10 women with long-term DMPA exposure. Tumors underwent histopathological analysis, targeted sequencing, and DNA methylation profiling. Data were integrated with reference cohorts (Baylor and Heidelberg) and analyzed through classifier assignment, consensus clustering, copy number analysis, differential methylation testing, and dimensionality reduction.

Results

Depot medroxyprogesterone acetate-associated meningiomas were all newly diagnosed, World Health Organization grade 1 tumors with a predilection for the anterior and central skull base (n = 6). Nine patients harbored multiple meningiomas. Four experienced regression of untreated meningiomas following DMPA cessation, while 5 demonstrated stabilization. Histopathology demonstrated relative overrepresentation of metaplastic morphology, an uncommon meningioma subtype. All DMPA-associated meningiomas mapped to benign molecular groups, and most exhibited low copy number alteration burden. Targeted sequencing revealed enrichment for TRAF7 mutations (n = 5), with no NF2 mutations detected. Eight tumors shared consensus cluster identity, with cohesive grouping on principal component analysis and t-distributed stochastic neighbor embedding. No differential methylation was identified at the progesterone receptor locus.

Conclusions

Depot medroxyprogesterone acetate-associated meningiomas represent a recognizable phenotype within the broader NF2-wildtype/TRAF7-enriched spectrum of benign meningiomas, characterized by chromosomal stability, a shared methylation profile, tumor multiplicity, and regression or stabilization following DMPA cessation. While derived from a small single-institution cohort, these findings provide a molecular framework for understanding progestin-associated meningioma biology, reinterpreting epidemiologic literature, and informing population-level risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMedroxyprogesterone AcetateMeningeal NeoplasmsGenomicsContraceptive Agents, FemaleBiomarkers, TumorContraceptive Agents, HormonalHumansFemaleMiddle AgedDNA MethylationAdultAgedPrognosis

Stichwörter der Autor:innen

depot medroxyprogesterone acetatemeningiomamethylationprogesteroneprogestin

Substanzen

Medroxyprogesterone AcetateContraceptive Agents, FemaleBiomarkers, TumorContraceptive Agents, Hormonal

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
  • Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA (D.R.R.).
  • Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
  • Department of Pathology, Division of Neuropathology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Department of Neurological Surgery, New York University Langone Medical Center, New York City, NY, USA.

ORCID-Profile: Sakibul Huq, Taylor A Gatesman, Hussam Abou-Al-Shaar, David R Raleigh, Constantinos G Hadjipanayis, James C Bayley, Thomas M Pearce, Daniel F Marker, Sameer Agnihotri, Paul A Gardner

Förderung

  • NINDS NIH HHS
  • NIH/NINDS

Zitieren

APA

Huq, S., Gatesman, T. A., Abou-Al-Shaar, H., Raleigh, D. R., Hadjipanayis, C. G., Bayley, J. C., Zenonos, G. A., Pearce, T. M., Marker, D. F., Agnihotri, S., & Gardner, P. A. (2026). Genomic hallmarks of depot medroxyprogesterone acetate-associated meningiomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag136

Vancouver

Huq S, Gatesman TA, Abou-Al-Shaar H, Raleigh DR, Hadjipanayis CG, Bayley JC, et al. Genomic hallmarks of depot medroxyprogesterone acetate-associated meningiomas. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag136

BibTeX
@article{Huq2026,
  author = {Huq, Sakibul and Gatesman, Taylor A and Abou-Al-Shaar, Hussam and Raleigh, David R and Hadjipanayis, Constantinos G and Bayley, James C and Zenonos, Georgios A and Pearce, Thomas M and Marker, Daniel F and Agnihotri, Sameer and Gardner, Paul A},
  title = {Genomic hallmarks of depot medroxyprogesterone acetate-associated meningiomas},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noag136}
}
Kostenlos starten →